-
Antiviral API
- Arenavirus
- Cytomegalovirus (CMV)
- Dengue virus
- Endogenous Metabolite
- Enterovirus (EV)
- Epstein-Barr virus (EBV)
- Filovirus
- Flavivirus
- HCV Protease
- Hepatitis B Virus (HBV)
- Hepatitis C Virus (HCV)
- Herpes simplex Virus (HSV)
- HIF/HIF Prolyl-Hydroxylase
- HIV Integrase
- HIV Protease
- Human immunodeficiency Virus (HIV)
- Human papillomavirus (HPV)
- Influenza Virus
- Nipah virus
- Orthopoxvirus
- Others
- Rabies virus (RABV)
- Respiratory syncytial Virus (RSV)
- Reverse Transcriptases (RTs)
- SARS-CoV
- Tobacco mosaic virus (TMV)
- Vesicular stomatitis virus (VSV)
- Virus Protease
- West Nile virus
- Antiviral intermediates
SARS-CoV-2-IN-12
![{PARAM:[Name]}()](https://resource.bocsci.com/structure/2721455-52-1.gif)
| Category | SARS-CoV |
| CAS | 2721455-52-1 |
| Description | SARS-CoV-2-IN-12 (Compound 27) is a potent SARS-CoV-2-related 3C-like protease inhibitor (Ki=32.1 pM) for preventing SARS-CoV-2 viral replication and that could be useful in the research of COVID-19. SARS-CoV-2 3C-like protease (3CLpro), an enzyme essential for viral replication, is an attractive target for intervention. SARS-CoV-2-IN-11 may lead to the emergence of effective SARS-CoV-2-specific antivirals. |
Product Information
| Synonyms | SARS-CoV-2-IN-12|CHEMBL4862866|HY-145435 |
| Molecular Weight | 697.7 |
| Molecular Formula | C32H42F3N5O9 |
| Canonical SMILES | CC(C)CC(C(=O)NC(CC1CCNC1=O)C(=O)COC(=O)C2CCCN2C)NC(=O)C3=CC4=C(N3)C=CC=C4OC.C(=O)(C(F)(F)F)O |
| Purity | ≥98% (HPLC) |
| Solubility | In vitro: 10 mM in DMSO |
| Appearance | Solid powder |
| Storage | Store at -20°C |
| Complexity | 1090 |
| Exact Mass | 697.29346242 |
| Target | SARS-CoV |
